An Acorda Therapeutics Inc. (ACOR) President and CEO Sells 2289.0 Shares


Acorda Therapeutics Inc. (NASDAQ:ACOR) traded with a subtraction of -$0.01 to $0.30 on Thursday, a downside of -3.84 percent. An average of 330,775 shares of common stock have been traded in the last five days. There was a fall of -$0.1114 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 183,734 shares traded, while the 50-day average volume stands at 223,440.

ACOR stock has decreased by -28.01% in the last month. The company shares reached their 1-month lowest point of $0.2766 on 09/22/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $0.28 and a high of $4.99 in 52 weeks. It has reached a new high 2 times so far this year and lost -87.03% or -$2.1014 in price. In spite of this, the price is down -94.03% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Insider Transactions

189 days have passed since Acorda Therapeutics Inc. (ACOR) last reported insider trading activity. COHEN RON, who is President and CEO, most recently acquired $2,289 shares at $1.70 per share on Mar 17.

Valuation Metrics

Acorda Therapeutics Inc. (ACOR) stock’s beta is 0.44. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.07, the price-to-book (PB) ratio at 0.06.

Financial Health

The quick ratio of Acorda Therapeutics Inc. for the three months ended September 29 was 1.50, and the current ratio was 1.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 2.10 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $88.28 million compared to revenue of $129.07 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Acorda Therapeutics Inc.’s return on assets was -27.10%.

Earnings Surprise

For the three-month period that ended September 29, Acorda Therapeutics Inc. had $26.3 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$46.68 million in the quarter, while revenues of -$24.52 million were grew 51.03%. The analyst consensus anticipated Acorda Therapeutics Inc.’s latest quarter earnings to come in at -$1.56 per share, but it turned out to be -$1.43, a 8.30% surprise. For the quarter, EBITDA amounted to -$1.24 million. Shareholders own equity worth $24.28 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Acorda Therapeutics Inc. (ACOR) price momentum. RSI 9-day as of the close on 21 September was 19.89%, suggesting the stock is oversold, with historical volatility in this time frame at 78.83%.

As of today, ACOR’s price is $0.3244 -27.85% or -$0.1114 from its 5-day moving average. ACOR is currently trading -31.45% lower than its 20-day SMA and -78.78% lower than its 100-day SMA. However, the stock’s current price level is -35.87% below the SMA50 and -88.55% below the SMA200.

The stochastic %K and %D were 7.80% and 14.98%, respectively, and the average true range (ATR) was 0.0385. With the 14-day stochastic at 8.07% and the average true range at 0.0386, the RSI (14) stands at 26.32%. The stock has reached -0.0482 on the 9-day MACD Oscillator while the 14-day reading was at -0.0597.

Analyst Ratings

H.C. Wainwright upgraded Acorda Therapeutics Inc. (NASDAQ: ACOR) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Acorda Therapeutics Inc. (ACOR) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ACOR, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.

What is ACOR’s price target for the next 12 months?

Analysts predict a range of price targets between $10.00 and $10.00, with a median target of $10.00. Taking a look at these predictions, the average price target given by analysts for Acorda Therapeutics Inc. (ACOR) stock is $10.00.


Please enter your comment!
Please enter your name here